Background and aim <p>Prediabetes is associated with metabolic disturbances that significantly increase the risk of developing cardiovascular disease (CVD). Probiotics and synbiotics may improve metabolic health, but their impact on CVD risk factors in prediabetic adults needs further evaluation. This meta-analysis evaluates the effects of probiotic and synbiotic supplementation on cardiovascular risk factors in individuals with prediabetes.</p> Methods <p>An extensive search of scientific databases was conducted from inception through February 2025 to identify relevant randomized controlled trials (RCTs). After screening, data were extracted. A random-effects model was used to compute pooled weighted mean differences (WMD) with 95% confidence intervals (CIs), accounting for study heterogeneity. All statistical analyses were performed using Stata.</p> Results <p>The pooled analysis of seven RCTs revealed that probiotics and synbiotics supplementation in prediabetic adults had no significant changes in fasting blood glucose (FBG) (WMD: -2.15&#xa0;mg/dL, <i>p</i> = 0.135), fasting insulin (FI) (WMD: -0.43 µIU/mL, <i>p</i> = 0.526), Homeostasis model assessment of insulin resistance (HOMA-IR) (WMD: -0.31, <i>p</i> = 0.090), triglycerides (TG) (WMD: -5.53&#xa0;mg/dL, <i>p</i> = 0.614), total cholesterol (TC) (WMD: -1.92&#xa0;mg/dL, <i>p</i> = 0.730), low-density lipoprotein cholesterol (LDL-C) (WMD: 1.39&#xa0;mg/dL, <i>p</i> = 0.542), systolic blood pressure (BP) (WMD: -2.24 mmHg, <i>p</i> = 0.480), diastolic BP (WMD: -1.10 mmHg, <i>p</i> = 0.260), body weight (WMD: 0.30&#xa0;kg, <i>p</i> = 0.861), and body mass index (BMI) (WMD: -0.20&#xa0;kg/m², <i>p</i> = 0.510). In contrast, a significant improvement was noted in hemoglobin A1c (HbA1c) levels (WMD: -0.16, <i>p</i> &lt; 0.001) and high-density lipoprotein cholesterol (HDL-C) (WMD: 1.63&#xa0;mg/dL, <i>p</i> = 0.020).</p> Conclusion <p>Probiotics and synbiotics show the potential to improve specific cardiovascular risk factors in prediabetic individuals, notably through reductions in HbA1c and an increase in HDL-C levels. However, their effects on other metabolic markers, such as FBG, insulin resistance, lipid profiles, and weight, remain inconclusive. Further high-quality trials are necessary to fully assess their impact on cardiovascular risks and diabetes progression in this population.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Effects of probiotics and synbiotics supplementation on cardiovascular risk factors in adults with prediabetes: a GRADE-assessed systematic review and meta-analysis of RCTs

  • Azin Setayesh,
  • Mehdi Karimi,
  • Hoda Haghshenas,
  • Mehdi Chegin,
  • Omid Asbaghi,
  • Sayed Hossein Davoodi,
  • Bagher Larijani

摘要

Background and aim

Prediabetes is associated with metabolic disturbances that significantly increase the risk of developing cardiovascular disease (CVD). Probiotics and synbiotics may improve metabolic health, but their impact on CVD risk factors in prediabetic adults needs further evaluation. This meta-analysis evaluates the effects of probiotic and synbiotic supplementation on cardiovascular risk factors in individuals with prediabetes.

Methods

An extensive search of scientific databases was conducted from inception through February 2025 to identify relevant randomized controlled trials (RCTs). After screening, data were extracted. A random-effects model was used to compute pooled weighted mean differences (WMD) with 95% confidence intervals (CIs), accounting for study heterogeneity. All statistical analyses were performed using Stata.

Results

The pooled analysis of seven RCTs revealed that probiotics and synbiotics supplementation in prediabetic adults had no significant changes in fasting blood glucose (FBG) (WMD: -2.15 mg/dL, p = 0.135), fasting insulin (FI) (WMD: -0.43 µIU/mL, p = 0.526), Homeostasis model assessment of insulin resistance (HOMA-IR) (WMD: -0.31, p = 0.090), triglycerides (TG) (WMD: -5.53 mg/dL, p = 0.614), total cholesterol (TC) (WMD: -1.92 mg/dL, p = 0.730), low-density lipoprotein cholesterol (LDL-C) (WMD: 1.39 mg/dL, p = 0.542), systolic blood pressure (BP) (WMD: -2.24 mmHg, p = 0.480), diastolic BP (WMD: -1.10 mmHg, p = 0.260), body weight (WMD: 0.30 kg, p = 0.861), and body mass index (BMI) (WMD: -0.20 kg/m², p = 0.510). In contrast, a significant improvement was noted in hemoglobin A1c (HbA1c) levels (WMD: -0.16, p < 0.001) and high-density lipoprotein cholesterol (HDL-C) (WMD: 1.63 mg/dL, p = 0.020).

Conclusion

Probiotics and synbiotics show the potential to improve specific cardiovascular risk factors in prediabetic individuals, notably through reductions in HbA1c and an increase in HDL-C levels. However, their effects on other metabolic markers, such as FBG, insulin resistance, lipid profiles, and weight, remain inconclusive. Further high-quality trials are necessary to fully assess their impact on cardiovascular risks and diabetes progression in this population.